Product Code: VMR11215790
Value Market Research's latest report on the Global Human Microbiome Market identified a significant growth in the industry over the last few years and anticipates it to grow considerably within the forecast period of 2021-2027.
The global human microbiome market report provides a complete evaluation of the market for the forecast period. The report consists of various segments as well as an analysis of the factors playing a significant role in the market. The factors include the drivers, restraints, challenges and opportunities and the impact of these factors on the market has been provided in the report. The drivers and restraints are classified as intrinsic factors while the opportunities and challenges are classified as extrinsic factors of the market. The global human microbiome market study provides an insight on the developments of the market in terms of revenue throughout the specified period.
This report provides a complete analysis for the global human microbiome market. An in-depth secondary research, primary interviews and in-house expert reviews are responsible for providing the market estimates for the global human microbiome market. These market estimates have been put together by studying the impact of different social, political and economic factors along with the current market dynamics that are affecting the global human microbiome market growth.
The report begins with the market overview, followed by a crisp executive summary. The Porter's Five Forces analysis covered in this study will assist in understanding the five forces namely buyers bargaining power, suppliers bargaining power, threat of new entrants, the threat of substitutes and the degree of competition in the global human microbiome market. It also helps to explain the various participants such as system integrators, intermediaries and end users within the market. The report by Value Market Research also focuses on the competitive landscape of the global human microbiome market.
The market analysis involves a section exclusively to list the major players of the global human microbiome market wherein our analysts provide an insight into the financial statements of all the key players along with its key development product. The company profile section in the report also provides a business overview and financial information. The companies provided in this section can be customized as per the client's requirement.
The Human Microbiome Market Report Segments the market as below:
By Product
- Probiotics
- Prebiotics
- Diagnostic Tests
- Drugs
- Other Products
By Disease
- Infectious Diseases
- Endocrine and Metabolic Disorders
- Gastrointestinal Diseases
- Cancer
- Other Diseases (Cardiovascular Diseases, Neurological Disorders, Dermatology Diseases, Immune-Modulated Disorders, and Hematological Disorders.)
By Application
By Technology Type
- Sequencing
- 16s rRNA sequencing method
- Whole-genome sequencing method
- Other Sequencing methods (shotgun metagenomic sequencing, transcriptomics, and targeted sequencing.)
- Other Genomic Technologies (Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), and DNA Microarrays)
TABLE OF CONTENTS
1 . PREFACE
- 1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
- 2.1. Highlights of Market
- 2.2. Global Market Snapshot
3 . HUMAN MICROBIOME - INDUSTRY ANALYSIS
- 3.1. Introduction - Market Dynamics
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Opportunities
- 3.5. Industry Trends
- 3.6. Porter's Five Force Analysis
- 3.7. Market Attractiveness Analysis
- 3.7.1 By Product
- 3.7.2 By Disease
- 3.7.3 By Application
- 3.7.4 By Technology
- 3.7.5 By Region
4 . VALUE CHAIN ANALYSIS
- 4.1. Value Chain Analysis
- 4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
- 4.3. List of Potential Buyers
- 4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend
5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK
- 5.1. Impact Analysis of Covid-19 Outbreak
- 5.1.1. Direct Impact on Production
- 5.1.2. Supply Chain and Market Disruption
- 5.1.3. Financial Impact on Firms and Financial Markets
- 5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
- 5.3. Market: Pre V/S Post COVID-19
- 5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
- 5.5. COVID-19: Micro and Macro Factor Analysis
6 . GLOBAL HUMAN MICROBIOME MARKET ANALYSIS BY PRODUCT
- 6.1 Overview by Product
- 6.2 Historical and Forecast Data
- 6.3 Analysis by Product
- 6.4 Probiotics Market by Regions
- 6.5 Prebiotics Market by Regions
- 6.6 Diagnostic Tests Market by Regions
- 6.7 Drugs Market by Regions
- 6.8 Other Products Market by Regions
7 . GLOBAL HUMAN MICROBIOME MARKET ANALYSIS BY DISEASE
- 7.1 Overview by Disease
- 7.2 Historical and Forecast Data
- 7.3 Analysis by Disease
- 7.4 Infectious Diseases Market by Regions
- 7.5 Endocrine and Metabolic Disorders Market by Regions
- 7.6 Gastrointestinal Diseases Market by Regions
- 7.7 Cancer Market by Regions
- 7.8 Other Diseases Market by Regions
8 . GLOBAL HUMAN MICROBIOME MARKET ANALYSIS BY APPLICATION
- 8.1 Overview by Application
- 8.2 Historical and Forecast Data
- 8.3 Analysis by Application
- 8.4 Therapeutics Market by Regions
- 8.5 Diagnostics Market by Regions
9 . GLOBAL HUMAN MICROBIOME MARKET ANALYSIS BY TECHNOLOGY
- 9.1 Overview by Technology
- 9.2 Historical and Forecast Data
- 9.3 Analysis by Technology
- 9.4 Genomics Market by Regions
- 9.5 Proteomics Market by Regions
- 9.6 Metabolomics Market by Regions
10 . GLOBAL HUMAN MICROBIOME MARKET ANALYSIS BY GEOGRAPHY
- 10.1. Regional Outlook
- 10.2. Introduction
- 10.3. North America
- 10.3.1. Overview, Historic and Forecast Data
- 10.3.2. North America By Segment
- 10.3.3. North America By Country
- 10.3.4. United State
- 10.3.5. Canada
- 10.3.6. Mexico
- 10.4. Europe
- 10.4.1. Overview, Historic and Forecast Data
- 10.4.2. Europe by Segment
- 10.4.3. Europe by Country
- 10.4.4. United Kingdom
- 10.4.5. France
- 10.4.6. Germany
- 10.4.7. Italy
- 10.4.8. Russia
- 10.4.9. Rest Of Europe
- 10.5. Asia Pacific
- 10.5.1. Overview, Historic and Forecast Data
- 10.5.2. Asia Pacific by Segment
- 10.5.3. Asia Pacific by Country
- 10.5.4. China
- 10.5.5. India
- 10.5.6. Japan
- 10.5.7. South Korea
- 10.5.8. Australia
- 10.5.9. Rest Of Asia Pacific
- 10.6. Latin America
- 10.6.1. Overview, Historic and Forecast Data
- 10.6.2. Latin America by Segment
- 10.6.3. Latin America by Country
- 10.6.4. Brazil
- 10.6.5. Argentina
- 10.6.6. Peru
- 10.6.7. Chile
- 10.6.8. Rest of Latin America
- 10.7. Middle East & Africa
- 10.7.1. Overview, Historic and Forecast Data
- 10.7.2. Middle East & Africa by Segment
- 10.7.3. Middle East & Africa by Country
- 10.7.4. Saudi Arabia
- 10.7.5. UAE
- 10.7.6. Israel
- 10.7.7. South Africa
- 10.7.8. Rest Of Middle East And Africa
11 . COMPETITIVE LANDSCAPE OF THE HUMAN MICROBIOME COMPANIES
- 11.1. Human Microbiome Market Competition
- 11.2. Partnership/Collaboration/Agreement
- 11.3. Merger And Acquisitions
- 11.4. New Product Launch
- 11.5. Other Developments
12 . COMPANY PROFILES OF HUMAN MICROBIOME INDUSTRY
- 12.1. Company Share Analysis
- 12.2. Market Concentration Rate
- 12.3. Embion Technologies S.A
- 12.3.1. Company Overview
- 12.3.2. Financials
- 12.3.3. Products
- 12.3.4. Recent Developments
- 12.4. ENTEROME SA
- 12.4.1. Company Overview
- 12.4.2. Financials
- 12.4.3. Products
- 12.4.4. Recent Developments
- 12.5. Evelo Biosciences Inc.
- 12.5.1. Company Overview
- 12.5.2. Financials
- 12.5.3. Products
- 12.5.4. Recent Developments
- 12.6. IGEN BIOLAB GROUP
- 12.6.1. Company Overview
- 12.6.2. Financials
- 12.6.3. Products
- 12.6.4. Recent Developments
- 12.7. 4D Pharma Plc.
- 12.7.1. Company Overview
- 12.7.2. Financials
- 12.7.3. Products
- 12.7.4. Recent Developments
- 12.8. Ferring Pharmaceuticals
- 12.8.1. Company Overview
- 12.8.2. Financials
- 12.8.3. Products
- 12.8.4. Recent Developments
- 12.9. Gnubiotics Sciences
- 12.9.1. Company Overview
- 12.9.2. Financials
- 12.9.3. Products
- 12.9.4. Recent Developments
- 12.10. YSOPIA Bioscience
- 12.10.1. Company Overview
- 12.10.2. Financials
- 12.10.3. Products
- 12.10.4. Recent Developments
- 12.11. ViThera Pharmaceuticals Inc.
- 12.11.1. Company Overview
- 12.11.2. Financials
- 12.11.3. Products
- 12.11.4. Recent Developments
- 12.12. Gnubiotics Sciences
- 12.12.1. Company Overview
- 12.12.2. Financials
- 12.12.3. Products
- 12.12.4. Recent Developments
- 12.13. Osel Inc.
- 12.13.1. Company Overview
- 12.13.2. Financials
- 12.13.3. Products
- 12.13.4. Recent Developments
- 12.14. SECOND GENOME THERAPEUTICS
- 12.14.1. Company Overview
- 12.14.2. Financials
- 12.14.3. Products
- 12.14.4. Recent Developments
- 12.15. Immuron Ltd.
- 12.15.1. Company Overview
- 12.15.2. Financials
- 12.15.3. Products
- 12.15.4. Recent Developments
- 12.16. OxThera AB
- 12.16.1. Company Overview
- 12.16.2. Financials
- 12.16.3. Products
- 12.16.4. Recent Developments
- 12.17. AOBiome
- 12.17.1. Company Overview
- 12.17.2. Financials
- 12.17.3. Products
- 12.17.4. Recent Developments
- 12.18. Vedanta Biosciences Inc.
- 12.18.1. Company Overview
- 12.18.2. Financials
- 12.18.3. Products
- 12.18.4. Recent Developments
Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies